| Diabetes Mellitus, Non-Insulin-Dependent
Caduet vs Kombiglyze XR
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Caduet vs Kombiglyze with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKombiglyze has a higher rate of injection site reactions vs Caduet based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kombiglyze but not Caduet, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Caduet
Kombiglyze
At A Glance
Oral
Daily
Calcium channel blocker + HMG-CoA reductase inhibitor
Oral
Once daily
DPP4 inhibitor + biguanide
Indications
- Hypertensive disease
- Stable angina
- Angina Pectoris, Variant
- Coronary Artery Disease
- Hyperlipidemia
- Heterozygous familial hypercholesterolemia [HeFH]
- Homozygous familial hypercholesterolemia [HoFH]
- Hyperlipoproteinemia Type III
- Hypertriglyceridemia
- Diabetes Mellitus, Non-Insulin-Dependent
- Coronary heart disease
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Hypertensive disease Amlodipine 5 mg orally once daily (initial); max 10 mg once daily; start at 2.5 mg in elderly, fragile, small adult, pediatric (>6 years), or patients with hepatic insufficiency.
Stable angina, Angina Pectoris, Variant Amlodipine 5-10 mg orally once daily; most patients require 10 mg for adequate effect.
Coronary Artery Disease Amlodipine 5-10 mg orally once daily; majority of patients in clinical studies required 10 mg.
Hyperlipidemia, Hyperlipoproteinemia Type III, Hypertriglyceridemia, Diabetes Mellitus, Non-Insulin-Dependent, Coronary heart disease Atorvastatin 10-80 mg orally once daily; start at 40 mg if LDL-C reduction >45% is required.
Heterozygous familial hypercholesterolemia [HeFH] Atorvastatin 10-80 mg orally once daily in adults; 10-20 mg once daily in pediatric patients >=10 years.
Homozygous familial hypercholesterolemia [HoFH] Atorvastatin 10-80 mg orally once daily in adults and pediatric patients >=10 years; starting dose 10-20 mg once daily.
Diabetes Mellitus, Non-Insulin-Dependent Administer once daily with the evening meal; individualize starting dose based on current regimen; max 5 mg saxagliptin/2,000 mg metformin HCl extended-release once daily; limit saxagliptin to 2.5 mg daily with strong CYP3A4/5 inhibitors; swallow tablets whole.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to amlodipine, atorvastatin, or any excipient in CADUET, including reactions such as anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- History of serious hypersensitivity reaction to saxagliptin, metformin HCl, or any ingredient in KOMBIGLYZE XR, including anaphylaxis, angioedema, or exfoliative skin conditions
Adverse Reactions
Most common Edema, dizziness, flushing, palpitations, nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Rhabdomyolysis, myositis, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, Stevens-Johnson syndrome, toxic epidermal necrolysis, gynecomastia
Most common (>=5%) Upper respiratory tract infection, urinary tract infection, headache (saxagliptin); diarrhea, nausea/vomiting (metformin)
Serious Lactic acidosis, pancreatitis, heart failure, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, vitamin B12 decrease
Postmarketing Pancreatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, bullous pemphigoid, cholestatic and hepatocellular liver injury
Pharmacology
CADUET combines amlodipine, a dihydropyridine calcium channel blocker that inhibits transmembrane calcium influx into vascular smooth muscle and cardiac muscle to reduce peripheral vascular resistance and blood pressure, with atorvastatin, a selective, competitive HMG-CoA reductase inhibitor that lowers plasma cholesterol by reducing cholesterol synthesis in the liver and increasing hepatic LDL receptor expression.
Kombiglyze XR combines saxagliptin, a competitive DPP4 inhibitor that slows incretin hormone (GLP-1, GIP) inactivation to enhance glucose-dependent insulin release and suppress glucagon, and metformin HCl, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Caduet
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Kombiglyze
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Caduet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Kombiglyze
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Caduet
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Kombiglyze
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Caduet.
No savings programs available for Kombiglyze.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CaduetView full Caduet profile
KombiglyzeView full Kombiglyze profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.